- Change Language
- Home
- Overview
- Subscribers
- Locations
- Newsroom
30 October: A study on the drug colchicine, an antimitotic drug used in the treatment of periodic febrile illnesses, familial Mediterranean fever, acute pericarditis, and gouty arthropathy, might help improved outcomes of patients with COVID-19.
The study was conducted in a hospital in New York city from 21 March to 2 May 2020 in patients 18 years and older. A group of 34 patients, who were confirmed positive on SARS-CoV-2 nasal swab PCR, were given colchicine in addition to standard of care, while 78 control patients, also with a positive nasal swab PCR, received only standard of care. Inflammatory markers were recorded and statistical analysis were performed.
Researchers concluded "our results show for the first time that colchicine given to patients admitted to the hospital with COVID-19-related symptoms may improve outcome and is associated with lower levels of inflammatory markers and faster normalization of these markers, including D-dimer, LDH, CRP, and ferritin. Our study suggests that colchicine might be an important addition to the armamentarium against COVID-19 and highlights the need for subsequent randomized and double-blinded control trials."
Source: Canadian Journal of Infectious Diseases and Medical Microbiology
Countering Misinformation & Disinformation: Practical Training for Organizations
Practical skills to detect, verify, and respond across an evolving information landscape
Additional data provided by
English
Japanese
